Subcutaneous tocilizumab 162mg/biweekly ( DrugBank: Tocilizumab )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05090410 (ClinicalTrials.gov)	March 3, 2021	30/9/2021	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ...	Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients ...	Rheumatoid Arthritis;JAK Inhibitor;IL-6 Inhibitor;Musculoskeletal Ultrasound;Biomarker	Drug: filgotinib 200mg/day;Drug: subcutaneous tocilizumab 162mg/biweekly	Atsushi Kawakami	Gilead Sciences	Recruiting	20 Years	N/A	All	400	Phase 3	Japan

First Previous1Next Last